1.
J Law Med Ethics
; 51(S1): 116-125, 2023.
Article
in English
| MEDLINE
| ID: mdl-38156356
ABSTRACT
This paper will review the strategies and learning trajectories followed to tap the opportunities opened by the successive waves of biotechnologies: early imitators followed by late imitators in the first generation of biosimilars (erythropoietin, insulins, interferons), and then sequential entry and skipping stages during the second generation (monoclonal antibodies).